ப்ரொஃபெஸர் ஆஃப் மருந்து இல் கொலம்பியா பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ரொஃபெஸர் ஆஃப் மருந்து இல் கொலம்பியா பல்கலைக்கழகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ரொஃபெஸர் ஆஃப் மருந்து இல் கொலம்பியா பல்கலைக்கழகம் Today - Breaking & Trending Today

Oncology expert calls for detecting first cancer cell


Oncology expert calls for detecting first cancer cell
National
April 17, 2021
LAHORE: “The First Cell”, latest book by Dr Azra Raza, Professor of Medicine at Columbia University, was launched by the Afkar-e-Taza ThinkFest Online. Dr Azra Raza was in conversation with the CEO of Shaukat Khanum Hospitals, Dr Aasim Yusuf.
Explaining the crux of her argument Dr Raza, who has been a practicing oncologist and cancer researcher for over four decades, noted that “We are obsessed with curing cancer but forget the patient.” This lack of empathy she said was criminal.
Speaking from her personal experience where her husband suffered and died from cancer, Dr Raza said “Unless we convey the extent of human anguish, we would not be doing justice to the patient or to the field.” Countering the long-held belief, Dr Raza emphasised “We are trained not to get involved, but the patients demand empathy.” ....

Aasim Yusuf , Azra Raza , Professor Of Medicine At Columbia University , Columbia University , Afkare Taza Thinkfest , Shaukat Khanum Hospitals , அஸ்ரா ர்யாஸா , ப்ரொஃபெஸர் ஆஃப் மருந்து இல் கொலம்பியா பல்கலைக்கழகம் , கொலம்பியா பல்கலைக்கழகம் , ஷௌுகத் காணும் மருத்துவமனைகள் ,

PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering


PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering
PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering
 
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vor Biopharma, has announced the pricing of its initial public offering (IPO) of 9,828,017 shares of common stock at a public offering price of $18.00  per share resulting in gross proceeds to Vor of approximately $176.9 million, before underwriting discounts and commissions and offering expenses to be paid by Vor.  The shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol “VOR” on Friday, February 5, 2021. The offering is expected to close on Tuesday, Febru ....

New York , United States , Columbia University , United Kingdom , San Francisco , Siddhartha Mukherjee , Broadridge Financial Solutions , Nicolaus Company Incorporated , Goldman Sachs , Professor Of Medicine At Columbia University , Capital Inc , Exchange Commission , Prospectus Department , Puretech Health , Goldman Sachs Co , Evercore Group , Initial Public , Tech Health , Founded Entity , Vor Biopharma , Nasdaq Global Market , Associate Professor , Pulitzer Prize Winning , All Maladies , Biopharma Announces Pricing , Equity Capital Markets ,